BR0206552A - Utilização de pelo menos uma quinoleìna, quinoleìna, e, composição farmacêutica - Google Patents

Utilização de pelo menos uma quinoleìna, quinoleìna, e, composição farmacêutica

Info

Publication number
BR0206552A
BR0206552A BR0206552-5A BR0206552A BR0206552A BR 0206552 A BR0206552 A BR 0206552A BR 0206552 A BR0206552 A BR 0206552A BR 0206552 A BR0206552 A BR 0206552A
Authority
BR
Brazil
Prior art keywords
sub
alkenyl
quinoline
alkynyl
cho
Prior art date
Application number
BR0206552-5A
Other languages
English (en)
Inventor
Mohamed Fakhfakh
Bruno Figadere
Alain Fournet
Xavier Franck
Reynald Hocquemiller
Eric Prina
Original Assignee
Inst Rech Developpement Ird
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Rech Developpement Ird, Centre Nat Rech Scient filed Critical Inst Rech Developpement Ird
Publication of BR0206552A publication Critical patent/BR0206552A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"UTILIZAçãO DE PELO MENOS UMA QUINOLEìNA, QUINOLEìNA, E, COMPOSIçãO FARMACêUTICA". A invenção refere-se à utilização de quinoleínas de fórmula geral (I) em que R~ 1~ representa H, C~ 1~ - C~ 15~, alquenila ou alquinila C~ 2~C~ 15~, -CHO; heteroarila, alquila C~ 1~ - C~ 15~, ou alquenila ou alquinila C~ 2~ - C~ 7~, contendo pelo menos um substituinte escolhido dentre O, halogênio, -OH, -CHO, COOH, ariloxicarbonila, alquiloxicarbonila C~ 2~ - C~ 8~, alqueniloxicarbonila C~ 3~ - C~ 9~, nitrila, arila, heteroarila, arilsulfona, alquilsulfona C~ 1~ - C~ 7~, tioalquila ou aminoalquila C~ 1~ - C~ 7~, alquenila C~ 2~ - C~ 7~, contendo pelo menos um substituinte escolhido dentre -NH~ 2~, alcóxi C~ 1~ - C~ 7~, fenóxi, cicloalquila C~ 3~ - C~ 6~ ou heteroariloxi; alquileno ou alquinila C~ 2~ - C~ 15~ contendo pelo menos uma trialquilsilila C~ 1~ - C~ 7~; R~ 2~, na posição 3, 6 ou 8, representa H; halogênio; -OH; -CHO; -COOH; alquila ou alcóxi C~ 1~ - C~ 7~ -NH2, alquenila C~ 2~ - C~ 7~, ou alquinila C~ 2~ - C~ 10~; R~ 1~ e R~ 2~ não sendo, todos os dois, H; para a preparação de um medicamento para tratar as co-infecções provocadas por protozoários e retrovírus.
BR0206552-5A 2001-01-17 2002-01-15 Utilização de pelo menos uma quinoleìna, quinoleìna, e, composição farmacêutica BR0206552A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0100580A FR2819507B1 (fr) 2001-01-17 2001-01-17 Quinoleines substituees pour le traitement de co-infections a protozoaires et a retrovirus
PCT/FR2002/000140 WO2002057238A1 (fr) 2001-01-17 2002-01-15 Quinoleines substituees pour le traitement de co-infections a protozoaires et a retrovirus

Publications (1)

Publication Number Publication Date
BR0206552A true BR0206552A (pt) 2004-03-23

Family

ID=8858905

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206552-5A BR0206552A (pt) 2001-01-17 2002-01-15 Utilização de pelo menos uma quinoleìna, quinoleìna, e, composição farmacêutica

Country Status (9)

Country Link
US (1) US7342026B2 (pt)
EP (1) EP1351940B1 (pt)
AT (1) ATE368030T1 (pt)
BR (1) BR0206552A (pt)
CA (1) CA2434063C (pt)
DE (1) DE60221348T2 (pt)
ES (1) ES2291438T3 (pt)
FR (1) FR2819507B1 (pt)
WO (1) WO2002057238A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0603871B8 (pt) * 2006-08-24 2021-05-25 Fundacao Univ De Brasilia composições farmacêuticas para o tratamento de tripanossomíases e de doença de chagas
KR20100108337A (ko) * 2007-11-15 2010-10-06 베링거 인겔하임 인터내셔날 게엠베하 사람 면역결핍 바이러스 복제의 억제제
CA2705318C (en) * 2007-11-15 2013-12-31 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
JP5285709B2 (ja) * 2007-11-16 2013-09-11 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスの複製阻害薬
EP2220084B1 (en) * 2007-11-16 2014-02-19 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
FR2929943B1 (fr) * 2008-04-15 2010-09-24 Inst Rech Developpement Ird Sels de quinoleines 2-substituees
FR2931479B1 (fr) * 2008-05-20 2012-12-07 I R D Nouveaux derives de quinoleines 2-substituees et un procede pour leur preparation
FR2933977B1 (fr) * 2008-07-18 2013-04-26 Centre Nat Rech Scient Derives heterocycliques utiles dans le traitement des maladies neurodegeneratives
WO2010144101A1 (en) * 2009-06-09 2010-12-16 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Next generation quinoloine methanols
CN103140474A (zh) 2010-07-02 2013-06-05 吉里德科学公司 治疗aids的萘-2-基乙酸衍生物
CN103209963A (zh) * 2010-07-02 2013-07-17 吉里德科学公司 作为hiv抗病毒化合物的2-喹啉基-乙酸衍生物
BR112013027096A2 (pt) 2011-04-21 2016-12-27 Gilead Sciences Inc compostos de benzotiazol e seu uso farmacêutico
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
MD20140063A2 (ro) 2012-04-20 2014-12-31 Gilead Sciences, Inc. Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
CN102690042A (zh) * 2012-05-28 2012-09-26 常熟市建华模具有限责任公司 一种用于制作玻璃容器用的模具
US9302992B2 (en) 2013-04-02 2016-04-05 Annji Pharmaceutical Co., Ltd. Multifunctional quinoline derivatives as anti-neurodegenerative agents
WO2014163622A1 (en) * 2013-04-02 2014-10-09 Annji Pharmaceutical Co., Ltd. Multifunctional quinoline derivatives as anti-neurodegenerative agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH471810A (de) * 1964-10-22 1969-04-30 Ciba Geigy Verfahren zur Herstellung von neuen heterocyclischen Verbindungen
ES8801209A1 (es) * 1985-06-18 1988-01-01 Merck Frosst Canada Inc Un procedimiento para la preparacion de quinolinas 2-sustituidas.
IL83715A0 (en) * 1987-08-31 1988-01-31 Yeda Res & Dev Pharmaceutical anti-protozoal compositions
US5153202A (en) * 1988-06-30 1992-10-06 Davis Michael H Method of inhibiting the activity of human immuno deficiency virus (HIV) in vivo
US5278173A (en) * 1988-06-30 1994-01-11 Davis Michael H Method of inhibiting the activity of human immunodeficiency virus (HIV) in vivo
US5360811A (en) * 1990-03-13 1994-11-01 Hoechst-Roussel Pharmaceuticals Incorporated 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
FR2682107B1 (fr) * 1991-10-03 1995-04-21 Orstom Inst Fs Rech Scient Quinoleines 2-substituees pour le traitement des leishmanioses.
GB9614347D0 (en) 1996-07-09 1996-09-04 Smithkline Beecham Spa Novel compounds
FR2761687B1 (fr) 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
WO2000044387A1 (fr) * 1999-01-29 2000-08-03 Nitto Kasei Co., Ltd. Composes organobores presentant une activite de coccidiostats
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
EP1206568A2 (en) * 1999-08-30 2002-05-22 K.U. Leuven Research & Development Target for antiparasitic agents and inhibitors thereof

Also Published As

Publication number Publication date
US20050165052A1 (en) 2005-07-28
US7342026B2 (en) 2008-03-11
WO2002057238A1 (fr) 2002-07-25
DE60221348T2 (de) 2008-04-10
FR2819507B1 (fr) 2007-09-28
DE60221348D1 (de) 2007-09-06
ES2291438T3 (es) 2008-03-01
EP1351940A1 (fr) 2003-10-15
EP1351940B1 (fr) 2007-07-25
CA2434063A1 (fr) 2002-07-25
ATE368030T1 (de) 2007-08-15
FR2819507A1 (fr) 2002-07-19
CA2434063C (fr) 2011-08-02

Similar Documents

Publication Publication Date Title
BR0206552A (pt) Utilização de pelo menos uma quinoleìna, quinoleìna, e, composição farmacêutica
NO2017022I1 (no) Obeticholinsyre
ATE366724T1 (de) Kondensierte heterocyclische derivate
DK1295890T3 (da) Hidtil ukendte pyrazinderivater eller salte deraf, farmaceutiske præparater, der indeholder derivaterne eller saltene, og mellemprodukter til fremstilling af begge
DK0620216T3 (da) Benzamidderivater og deres anvendelse som vasopressinantagonister
CA2445190A1 (en) Indole, azaindole and related heterocyclic amidopiperazine derivatives
BR0214876A (pt) Formas de sal de e-2-metóxi-n-(3-(4-(3-metil-piridin-3-ilóxi)-fenilamino)qui nazolin-6-il)-alil)-acetamida, suas preparações e uso dos mesmos contra o câncer
NO20004485D0 (no) Sykloalkenderivater, deres fremstilling og anvendelse
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
EA200400086A1 (ru) Новые производные оксазолидинонов в качестве антибактериальных агентов
NO940245D0 (no) Quinolin eller quinazolinderivater, deres fremstilling og anvendelse
HUP0302193A2 (hu) 1,4-Diazabiciklo[3.2.2]nonán-benzoxazol,-benzotiazol és -benzimidazol-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
DK1970372T3 (da) Salte af 9-oxoacridin-10-eddikesyre med 1-alkylamino-1-deoxy-polyoler
ATE172454T1 (de) Pyridazinon derivate mit pharmazeutischer wirkung
DK1175429T3 (da) Halogenderivater af 9-deoxo-9a-aza-9a-homoerythromycin A
ATE205209T1 (de) Chinolincarbonsäurederivate und ihre salze
RU2004103857A (ru) Производные вариолина и их применение в качестве противоопухолевых средств
DK0410305T3 (da) Anvendelse af bis(4-hydroxyphenylthio)methanderivater til behandling af diabetes mellitus
EE9900582A (et) 5-asendatud-1,2,4-tiadiasolüülderivaadid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon, vaheühend ja selle valmistamismeetod
NO20000114D0 (no) 2,4,4-trisubstituerte-1,3-diokolan-antifungale midler
BR0206206A (pt) Derivados de etoposide e análogos, e composições farmacêuticas contendo os mesmos
BR0201312A (pt) Compostos de pirimidin-4-ona, processo para sua preparação e composições farmacêuticas contendo os referidos
SE8500963D0 (sv) Nitraminodiaryl sulfoxide derivatives, process for their preparation and pharmaceutical and pesticidal compositions containing them
TH127941A (th) อนุพันธ์อะมิโนไธแอโซล การเตรียมอนุพันธ์เหล่านี้ และองค์ประกอบทางเภสัชกรรมที่มีอนุพันธ์เหล่านี้

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2258 DE 15/04/2014.